Prognostic factors including injection frequency, hypertension, hyperlipemia and ELM disruption may all be useful to provide predictive information of visual outcome of RVO patients in response to anti-VEGF treatment. The gene discussed is VEGFA; the disease is familial hyperlipidemia.